Clinical Impact, Regulatory Wins, and Trusted Innovation

CEO Update Q2 2025

This quarter, the impact of EndoTool came into even sharper focus – not just through what we say, but through what our customers are proving in practice.

At this year’s AACE Annual Meeting, new research from Corewell Health showed how EndoTool is driving measurable impact for patients with diabetic ketoacidosis (DKA) reducing both length of stay and direct cost of care.

Just as importantly, the study highlighted improved safety in patients with renal impairment, a group often at greater risk from traditional insulin dosing protocols.

At the American Diabetes Association Scientific Sessions, Temple Health joined the conversation with an impressive presentation on their results using EndoTool SubQ.

Their team reported a 71% reduction in hypoglycemia and an 85% drop in severe hypoglycemia after switching to EndoTool SubQ – offering evidence of what can be achieved with patient-specific insulin dosing outside the ICU.

It was energizing to be at the ADA in person, hearing firsthand how the conversation around inpatient glycemic management is evolving.

The growing emphasis on individualized care – especially for complex and high-risk patients – only reinforced what we’ve long believed: precision matters.

Raising the Bar on Trust and Clinical Confidence

In Q2, we also reaffirmed our commitment to innovation with the public announcement of our FDA 510(k) clearance for EndoTool IV 3.1.

This clearance expands EndoTool’s indication for managing hyperglycemic crises, including DKA and EuDKA, and strengthens our leadership in delivering safe, scalable insulin dosing – especially for the most complex cases.

Looking Ahead

Independent, peer-reviewed research continues to show that EndoTool delivers results that matter: shorter hospital stays, reduced hypoglycemia, safe insulin dosing in high-risk populations, and real financial impact.

If you or your health system are interested in conducting studies on the impact EndoTool is having on clinical or operational outcomes, we’d love to collaborate. Please reach out to our Chief Medical Officer, Dr. Paul Chidester, to explore what is possible.

As we look ahead to the second half of the year, we’re energized by the momentum we’re building.

We’ll continue to innovate, partner, and lead – because we believe the future of glycemic care should be truly patient-specific.